Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan

Eitemau Tebyg

• Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
  gan: Tanaka, Yoshiya, et al.
  Cyhoeddwyd: (2019)
• Correction to: Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan
  gan: Yoshiya Tanaka, et al.
  Cyhoeddwyd: (2019-04-01)
• Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial
  gan: Strand, Vibeke, et al.
  Cyhoeddwyd: (2016)
• Long-term safety and efficacy of sarilumab plus methotrexate on disease activity, physical function and radiographic progression: 5 years of sarilumab plus methotrexate treatment
  gan: Genovese, Mark C, et al.
  Cyhoeddwyd: (2019)
• Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY
  gan: Boyapati, Anita, et al.
  Cyhoeddwyd: (2016)